Brandl Andreas, Kratzer Theresa, Kafka-Ritsch Reinhold, Braunwarth Eva, Denecke Christian, Weiss Sascha, Atanasov Georgi, Sucher Robert, Biebl Matthias, Aigner Felix, Pratschke Johann, Öllinger Robert
From the Department of Visceral, Transplant and Thoracic Surgery, Medical University, Innsbruck, Austria (Brandl, Kratzer, Kafka-Ritsch, Braunwarth, Weiss); the Department of General, Visceral, Vascular and Thoracic Surgery, Charité Campus Mitte, Berlin, Germany (Brandl, Atanasov, Pratschke); and the Department of General, Visceral and Transplant Surgery, Charité Campus Virchow-Klinikum, Berlin, Germany (Denecke, Sucher, Biebl, Aigner, Pratschke, Öllinger).
Can J Surg. 2016 Aug;59(4):254-61. doi: 10.1503/cjs.012915.
Diagnosis and treatment of diverticulitis in immunosuppressed patients are more challenging than in immunocompetent patients, as maintenance immunosuppressive therapies may mask symptoms or impair the patient's ability to counteract the local and systemic infective sequelae of diverticulitis. The purpose of this study was to compare the in-hospital mortality and morbidity due to diverticulitis in immunosuppressed and immunocompetent patients and identify risk factors for lethal outcomes.
This retrospective study included consecutive in-patients who received treatment for colonic diverticulitis at our institution between April 2008 and April 2014. Patients were divided into immunocompetent and immunosuppressed groups. Primary end points were mortality and morbidity during treatment. Risk factors for death were evaluated.
Of the 227 patients included, 15 (6.6%) were on immunosuppressive therapy for solid organ transplantation, autoimmune disease, or cerebral metastasis. Thirteen of them experienced colonic perforation and showed higher morbidity (p = 0.039). Immunosuppressed patients showed longer stays in hospital (27.6 v. 14.5 d, p = 0.016) and in the intensive care unit (9.8 v. 1.1 d, p < 0.001), a higher rate of emergency operations (66% v. 29.2%, p = 0.004), and higher in-hospital mortality (20% v. 4.7%, p = 0.045). Age, perforated diverticulitis with diffuse peritonitis, emergency operation, C-reactive protein > 20 mg/dL, and immunosuppressive therapy were significant predictors of death. Age (hazard ratio [HR] 2.57, p = 0.008) and emergency operation (HR 3.03, p = 0.003) remained significant after multivariate analysis.
Morbidity and mortality due to sigmoid diverticulitis is significantly higher in immunosuppressed patients. Early diagnosis and treatment considering elective sigmoid resection for patients with former episodes of diverticulitis who are wait-listed for transplant is crucial to prevent death.
免疫抑制患者憩室炎的诊断和治疗比免疫功能正常的患者更具挑战性,因为维持性免疫抑制治疗可能掩盖症状或损害患者对抗憩室炎局部和全身感染后遗症的能力。本研究的目的是比较免疫抑制患者和免疫功能正常患者因憩室炎导致的住院死亡率和发病率,并确定致死结局的危险因素。
这项回顾性研究纳入了2008年4月至2014年4月期间在我院接受结肠憩室炎治疗的连续住院患者。患者分为免疫功能正常组和免疫抑制组。主要终点是治疗期间的死亡率和发病率。评估死亡的危险因素。
在纳入的227例患者中,15例(6.6%)因实体器官移植、自身免疫性疾病或脑转移接受免疫抑制治疗。其中13例发生结肠穿孔,发病率更高(p = 0.039)。免疫抑制患者住院时间更长(27.6天14天对14.5天,p = 0.016),在重症监护病房的时间更长(9.8天对1.1天,p < 0.001),急诊手术率更高(66%对29.2%,p = 0.004),住院死亡率更高(20%对4.7%,p = 0.045)。年龄、伴有弥漫性腹膜炎的穿孔性憩室炎、急诊手术、C反应蛋白>20mg/dL和免疫抑制治疗是死亡的重要预测因素。多因素分析后,年龄(风险比[HR]2.57,p = 0.008)和急诊手术(HR 3.03,p = 0.003)仍然具有显著性意义。
免疫抑制患者乙状结肠憩室炎导致的发病率和死亡率显著更高。对于等待移植的既往有憩室炎发作的患者,考虑择期乙状结肠切除术进行早期诊断和治疗对于预防死亡至关重要。